KIT and peripheral arterial disease: Another reason is that some PAD (e.g., STAT5b GOF, KIT, and ADGRE2 gene mutations) could have a prominent clinical and laboratory feature of hypereosinophilia or aberrant mast cell activation, which do not fit with the definition of “hyper‐IgE syndromes” in the IUIS classification.